- News & Events
News & Events
Genix will now be called Qualicaps®
Sao Paulo, May 2018 – From May 02nd, Genix will be called Qualicaps®. Acquired at the end of 2015 by Qualicaps®, a wholly owned subsidiary of Mitsubishi Chemical Holdings Corporation, the Brazilian company has been in operating for 13 years. It is the national leader in the production of two-piece hard capsules for the pharmaceutical industry, as well as for nutraceutical products, and is recognized for the excellence of its international standards of technology. The Company is certified for Good Manufacturing Practices and Pharmaceutical Ingredients by ANVISA – the Brazilian Health Regulatory Agency.
In two years since the company has formed part of Qualicaps®, the subsidiary has grown by 18,7% in its operation and currently employs 340 people in the country. It is also the only supplier of hard capsules with a production center in Brazil, consolidating Qualicaps® as the leader in the country that is the eighth largest pharmaceutical market in the world.
“Changing the company’s name is part of a natural process, due to the recognition of our technological quality by our customers and regulators, by the growth in our operation and by the perspective of greater regional performance. Latin America is a strategic market for Qualicaps®, which was already developing partnerships in other regions and identified in Genix the real possibility of covering this market and becoming the number one supplier of the pharmaceutical industry,” says Paulo Valente, President for Latin America.
With more than a century of experience and a strong history of pioneering in new forms of drug administration, Qualicaps® is responsible for several milestones in the development of hard capsules, introducing features that have become standard in the industry, such as being the first to create formulas without preservatives for gelatin capsules, and to develop capsules from vegetable origin (HPMC) for the pharmaceutical market.
In addition to the Brazilian factory, Qualicaps® has a global presence with manufacturing units in Japan, Spain, Romania, Canada, and the United States. The Brazilian subsidiary is responsible for serving the pharmaceutical and consumer healthcare markets in Latin America. Only in Brazil, the pharmaceutical market is expected to grow about 3.5% between 2018 and 2021, registering nearly US$ 30 billion in 2021, according to Global Health Intelligence.
- Engineered to perform
CPhI Middle East & Africa, September 16–18, 2019
For the second time, the CPhI Middle East & Africa event is meant to become the region's most comprehensive pharmaceutical platform. Together, with its co-located events iCSE, P-MEC, InnoPack and FDF, where over 4,900 key visiting pharma suppliers and buyers, along with a wide range of exhibitor from all across the entire pharma supply chain will meet and network under one roof. We would be pleased to welcome you in our booth G80 to introduce you our product and service offering for the hard capsule dosage form throughout the drug product life cycle.
Interphex Japan 2019, July 3-5, 2019
INTERPHEX JAPAN is the Japan’s largest trade show specialized in Pharmaceutical R&D and Manufacturing. We are pleased to inform you that we will be exhibiting some of our machines at INTERPHEX JAPAN 2019 held from July 3rd (Wed) to July 5th (Fri), 2019 at Tokyo Big Sight, Japan. We would be delighted if you could arrange your schedule and take opportunity to visit our booth. We look forward to seeing you at our booth.
Get to know the Qualicaps® team at Interphex 2019 in Tokyo Big Sight at Booth W8-002
CONSULFARMA 2019, July 11-13, 2019
The 14º Congress Consulfarma to be held in São Paulo from July 11th to 13th, will bring together important health and nutrition professionals, pharmacists, as well as compounding pharmacies and the main firms of the sector. During this three-day event, the key pharmaceutical companies will be presenting their novelties and showing their products launches, new assets, trends, product market and knowledge.
Get to know the Qualicaps® team at Consulfarma 2019 in São Paulo (Brazil) at booth 87.
FCE Pharma, May 21-23, 2019
FCE Pharma - International Pharmaceutical Technology Trade Show took place in May 2017, São Paulo. FCE Pharma is the biggest marketing and sales platform, playing an important role in the growth of the pharmaceutical industry not only by launching trends, products and services, but also with discussion of cases, sharing of content and experiences at conferences and talks. Get to know the Qualicaps® team at FCE PHARMA 2019 in São Paulo (Brazil) at Stand F075.
CPhI North America, April 30 – May 2, 2019
For nearly 30 years, CPhI has organized the world’s most influential pharmaceutical events. Several annual gatherings comprise our iconic worldwide portfolio, but it’s CPhI North America that has become the critical link in a global chain connecting motivated buyers with industry-leading suppliers. We represent the most lucrative pharma market on earth. It’s here you will drive your career and your business forward. You simply can’t afford to be left behind.
Vitafoods, May 7-9, 2019
Vitafoods Europe is a premium event within the nutraceutical industry where key players come together to create business opportunities, source ingredients, raw materials, services and dietary supplements from the nutraceutical market, and share knowledge about the latest regulation and market trends.
We would be delighted if you arrange your schedule and take the opportunity to visit us and learn about our hard capsule product offering for consumer healthcare. Qualicaps® Nutra’V and Nutra’G line of hard capsules are engineered from the environment, carved from its elements, to represent the best of 'nature + science' in shaping the state of well-being.
Get to know the Qualicaps® team at Vitafoods 2019 in Geneva (Switzerland) at Stand L104.
RDD Europe, May, 7-10, 2019
Respiratory Drug Delivery (RDD®) Europe 2019 is a major three-day symposium that focuses on the development and commercialization of pulmonary and nasal pharmaceutical products. The event, held this year at the Estoril Congress Center in Lisbon (Portugal) from May 7th – 10th, offers attendees the opportunity to take part in a leading conference that features in-depth presentations and discussions of pioneering respiratory drug delivery science. Qualicaps® is proud to be an Exhibit Sponsor of this edition, with participation from our Scientific Business Development team, including its Director, Susana Ecenarro, who together with Dr. Sion Coulman of the Cardiff School of Pharmacy and Pharmaceutical Sciences will present the Workshop: The performance of hard shell capsules for use in dry powder inhalers. We encourage you to attend the workshop and to visit the Qualicaps team at our Exhibition Table.
Get to know the Qualicaps® team at RDD 2019 in Lisbon.
Interphex, April 2-4 2019
Interphex USA is the premier pharmaceutical, biotechnology, and device development and manufacturing event held in New York City. This event brings 11,000 global industry leaders and 650+ suppliers together each year. Qualicaps® is pleased to be exhibiting at Interphex USA held April 2-4. 2019 at Javits Center, NYC. We will be introducing our latest UV Laser printers, LIS-Labo and QUALIS. We would be delighted if you could arrange your schedule and take the opportunity to visit our booth #3021A.
We look forward to seeing you at our booth.
Get to know the Qualicaps® team at Interphex USA at 3021A.
Qualicaps Romania site in Bucharest receives EXCiPACT GMP certification as pharmaceutical excipient suppliers
BRUSSELS, 24 January 2019
EXCiPACT asbl is pleased to announce that the Qualicaps Romania site in Bucharest, Romania has recently been awarded an EXCiPACT GMP Certificate from AENOR, one of EXCIPACT’s internationally-recognised Certification Bodies. The Certificate demonstrates that this site manufactures pharmaceutical excipients according to the EXCiPACT Good Manufacturing Practice (GMP) Certification Standard. Its scope covers manufacture of gelatin capsule shells for the pharmaceutical and consumer health industries.
Both AENOR and their auditors had to undergo a rigorous assessment process in order to be EXCiPACT Registered. Both have satisfied the additional EXCiPACT competency requirements set out in the EXCiPACT annex to the ISO/IEC 17021-1:2015 standard. In addition, their auditors have successfully completed the 2-day EXCiPACT Auditor Training Course and post-course written examination followed by an independently witnessed audit to verify that their competency is to the required standard. AENOR also had to have their auditor’s report verified by an independent certification board prior to issuing the certificate.
For full details of all sites that have been EXCiPACT certified to date in 16 Countries (Canada, China, Belgium, France, Germany, India, Israel, Italy, Japan, Saudi Arabia, Singapore, Spain, Switzerland, The Netherlands, UK and USA), see http://www.excipact.org/certificate-holders.html.
EU and U.S. pharmaceutical regulations require drug manufacturers to conduct either their own or commission third-party physical audits of all their starting material suppliers to demonstrate GMP and/ or GDP compliance thus increasing the audit burden. However, using GMP and GDP standards designed specifically for pharmaceutical excipients, the independent, high quality EXCiPACT Certification Scheme helps pharmaceutical excipient users and their suppliers to demonstrate their commitment to GMP/GDP, to reduce their audit burden, to save costs and to assure quality.
Capsule-based DPIs – Understanding the science
Drug delivery via the pulmonary route is well established for the treatment of localised diseases such as asthma and COPD, though it has attracted attention recently as a portal for systemic diseases as well. A number of devices exist in the market to facilitate inhaled drug delivery, each with its particular advantages and disadvantages. One such type of device is a dry powder inhaler (DPI).
Some DPIs operate with hard shell capsules as single unit drug reservoirs that are punctured in situ prior to aerosolisation. Many capsule formulations have been used in DPIs, and as these may behave differently, it is important to understand which key capsule characteristics determine their suitability.
This webinar will discuss several capsule formulations used in DPIs and will compare their performance. It will provide an overview on some of the novel methods being employed to evaluate the physical characteristics and mechanical properties of capsules, and will also address the factors influencing the aerosolisation performance of different capsule types.
Key learning objectives:
- Key advantages of DPIs and considerations when choosing a hard capsule
- Overview on some of the novel methods being employed to evaluate the physical characteristics and mechanical properties of capsules
- Key factors influencing the aerosolization and aerodynamic performance of different capsule types
Our webinar is free and open to anyone who wants a better understanding of the relevant aspects when undertaking a new drug development cost/benefit analysis, as well as the versatility and positive appreciation of the capsule solid oral dosage form.
To view the webinar in on demand mode, click on the link below to register